by Csequence | Aug 5, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News July 29th – August 5th, 2022 Cannabis Use to Treat Perimenopause and Postmenopause Symptoms: Results from Survey 86.1% of participants reported using cannabis, with 78.7% to treat menopausal-related symptoms. There are 3 types of menopauses...
by Csequence | Aug 5, 2022 | Communications, Weekly Cannabis News
Menopause, Anxiety Disorders, and Nociception: Weekly Cannabis News July 29th-August 5th, 2022
by Csequence | Aug 3, 2022 | Communications, Weekly Cannabis News
July 22nd – July 29th, 2022 Effects of Cannabinol (CBN)-Based Solution in Mice Study results indicate that the water-soluble cannabinol compound, CBNight™ does not cause significant toxicity. Discovered nearly a century ago, cannabinol, otherwise known as CBN, is a...
by Csequence | Jul 28, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News July 8th – July 15th, 2022 Cannabidiol Derivative & Traumatic Brain Injury (TBI) VCE-004.8 demonstrated anti-inflammatory and protective effects, suggesting that this compound could open new therapeutic avenues for the treatment of TBI....
by Csequence | Jul 28, 2022 | Communications, Weekly Cannabis News
Weekly Cannabis News July 1st – July 8th, 2022 The Use of Medical Cannabis as an Alternative Agent for Opioids in Managing Musculoskeletal Pain A new study found that patients suffering from musculoskeletal pain conditions reported notable reductions in pain...
by Csequence | Jul 28, 2022 | Communications, Weekly Cannabis News
July 8th – July 15th, 2022 Cannabidiol Derivative & Traumatic Brain Injury (TBI) VCE-004.8 demonstrated anti-inflammatory and protective effects, suggesting that this compound could open new therapeutic avenues for the treatment of TBI. According to the Centers...
Some text her explaining our event planning services.
For more info, contact us:
events@csequence.com